Apellis Pharmaceuticals receives FDA approval of EMPAVELI® (pegcetacoplan)

Written By Kimberly Hicks
Kimberly Hicks
Previous

Alnylam Pharmaceuticals continues to lead in RNAi therapeutics with a standout quarter!
Next

argenx Kicks Off 2025 with Record-Breaking Growth